XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2022

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

7. Accounts Payable and Accrued Expenses:

Accounts payable and accrued expenses consist of the following (in thousands):

		September 30, 2022		December 31, 2021
Accounts payable		$27,136		$36,645
Accrued salaries and incentive compensation		142,515		213,974
Accrued payroll taxes and benefits		37,191		34,994
Accrued professional liabilities		32,072		37,729
Accrued interest		3,520		29,052
Accrued contingent consideration		2,022		—
Other accrued expenses		62,004		41,724
		$306,460		$394,118

The net decrease in accrued salaries and incentive compensation of $71.5 million, from December 31, 2021 to September 30, 2022, is primarily due to the payment of performance-based incentive compensation, principally to the Company’s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September 30, 2022. A majority of the Company’s payments for performance-based incentive compensation is paid annually during the first quarter.

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration